Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib

N/ATerminatedNCT00320918

University of New Mexico10 enrolled

Overview

Chart Review on Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib.

As above.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cholangiocarcinoma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib. Exclusion Criteria: * Not specified.

Locations (1)

University of New Mexico

Albuquerque, New Mexico, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.